Information Provided By:
Fly News Breaks for November 25, 2019
Nov 25, 2019 | 06:38 EDT
UBS analyst Jacob Navin initiated coverage of Rapt Therapeutics with a Buy rating and $26 price target. The analyst contends that the pre-clinical data for the company's two lead CCR4 antagonists for multiple indications could make it an "interesting" acquisition target for both oncology and immunology pipelines.
News For RAPT From the Last 2 Days
There are no results for your query RAPT